MDRNA announced this week that it has begun a research study with Pfizer focused on RNAi drug discovery.

Under the deal, MDRNA will formulate Pfizer's oligonucleotides in its proprietary di-alkylated amino acids, or DiLA2, delivery vehicles for in vivo evaluation by the drugs giant. MDRNA will also design and synthesize UsiRNAs, duplex RNAs containing at least one non-nucleotide monomer, against Pfizer-specified targets.

Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.